Yellow Fever Vaccine Supply Strained as Manufacturing Bottlenecks Threaten Outbreak Readiness

Yellow fever, a mosquito-borne viral disease that can progress from a flu-like illness to jaundice, bleeding, and organ failure, remains a persistent threat in parts of Africa and the Americas. Public health officials have long relied on a powerful tool: a live attenuated vaccine derived from the 17D strain that, in most studies, produces protective antibodies in the overwhelming majority of recipients after a single dose. The problem is not scientific—it is industrial. Yellow fever vaccine is complex to manufacture, slow to scale, and vulnerable to sudden demand spikes when outbreaks erupt.

That vulnerability became starkly visible during the major outbreak that began in late 2015 in Angola and spread into the Democratic Republic of Congo (DRC). Across the two countries, the epidemic generated hundreds of confirmed infections and thousands of suspected cases, triggering an emergency response that consumed tens of millions of vaccine doses. The strain was so intense that the global emergency stockpile maintained for outbreak response was repeatedly drawn down, highlighting a central dilemma: when supplies cannot be replenished quickly, how can limited vaccine be stretched to protect the maximum number of people?

One answer—endorsed for emergencies by global health authorities—has been “fractional dosing,” in which a partial amount from each vial is administered to each person. Typically this means one-fifth of the standard volume. Dose-sparing approaches had been tested before in adults, with studies indicating that reduced quantities of vaccine could still generate strong immune responses. But a critical question lingered for outbreak planners: would fractional dosing hold up not only in controlled research settings, but in the messy realities of mass campaigns, including among children in endemic regions?

A large immunogenicity assessment embedded in the DRC response provides some of the clearest real-world evidence to date. In August 2016, facing inadequate supply for a fast-moving prevention campaign in Kinshasa—a city of many millions—health authorities implemented fractional dosing under emergency guidance. Approximately 7.6 million people were targeted over about 10 days, with fractional-dose 17DD vaccine (one-fifth of the standard dose, delivered as 0.1 ml) offered to nonpregnant adults and to children aged 2 years or older.

Researchers evaluated immune responses among participants recruited at selected vaccination sites representing different parts of the city. People were enrolled across four age bands (2–5, 6–12, 13–49, and 50+ years), reflecting the campaign’s broad reach. Blood samples were taken before vaccination and then again about one month and one year later. The team used a standard laboratory method—measuring neutralizing antibodies with a plaque reduction neutralization test (PRNT50)—to determine whether participants had antibody levels consistent with seropositivity. Those who lacked detectable antibodies at baseline and later crossed the threshold were counted as having seroconverted.

The results were striking. Among 716 participants who completed the one-month follow-up, 98% were seropositive after vaccination, with tight statistical confidence bounds. Focusing specifically on those who started without detectable antibodies, 98% seroconverted by one month. The study also included participants who already had antibodies at baseline—consistent with prior vaccination or prior exposure—and found that about two-thirds showed a strong boosting response, defined as at least a fourfold rise in antibody titer. Those with lower starting titers were more likely to mount that marked increase, a pattern immunologists would expect when baseline immunity is present but modest.

Durability, a key concern for any dose-sparing strategy, also looked encouraging. Among 684 participants with one-year follow-up, 97% remained seropositive. In other words, nearly everyone who achieved seropositivity shortly after fractional dosing still had antibody levels above the threshold a year later. Researchers also reported that antibody titer distributions differed by age, underscoring that children and older adults may not respond identically—a reminder that “works” is not the same as “works equally for everyone,” and that age-stratified monitoring matters.

Taken together, the findings bolster the rationale for fractional dosing as a pragmatic tool for outbreak control when supplies are insufficient. They also move the evidence base beyond small adult cohorts by showing performance in a campaign environment that included young children (from age two) as well as older adults. Importantly, the strategy does not aim to replace routine vaccination programs. Rather, it is designed for extraordinary circumstances—when the alternative is not full-dose vaccination, but leaving large numbers of people unprotected.

Even with strong immunogenicity data, fractional dosing raises operational and policy questions: training vaccinators to deliver smaller volumes accurately, ensuring safe injection practices at scale, communicating clearly to the public about what “fractional” means, and determining how long protection lasts compared with standard dosing. But the Kinshasa experience suggests that, during supply crises, dose-sparing can turn scarcity into coverage.

Why it matters

Yellow fever outbreaks can expand rapidly in densely populated areas, while vaccine production cannot surge overnight. Fractional dosing offers a way to protect far more people with the same finite stock, potentially slowing transmission and preventing deaths. As climate, urbanization, and mobility reshape mosquito-borne disease risk, strategies that maximize limited countermeasures are becoming a cornerstone of epidemic preparedness.